Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Merck & Co Inc
EIR
•Merck & Co Inc•June 14, 2013

Merck & Co Inc – FDA EIR, Jun 14, 2013

Record Details

An FDA inspection was conducted at Merck & Co Inc's Summit, NJ facility from June 10 to June 14, 2013. The primary objective was a high-priority pre-approval bioequivalence data validation of the sponsor's bioanalytical laboratory. This inspection, carried out under the regulatory framework of In Vivo Bioequivalence, CPGM 7348.001, aimed to verify data for study P05615, which supported New Drug Application (NDA) 205-053 for posaconazole. The inspection focused on the bioanalytical portion of the bioequivalence study, including personnel qualifications, training records, method validation, study testing procedures and records, laboratory notebooks, and sample handling documentation. Crucially, the FDA inspection concluded with no objectionable conditions observed. Consequently, a Form FDA-483 (Inspectional Observations) was not issued, and the inspection was classified as "No Action Indicated" (NAI). No refusals were encountered, and no samples were collected. While an unrelated consumer complaint concerning a foreign material in an over-the-counter product (Coricidin HPB Flu Tablets) was reviewed, it was distinct from the bioequivalence study scope, and Merck indicated ongoing monitoring without further direct action from this specific inspection finding. No specific required actions were identified for Merck as a result of this inspection.

Company
Merck & Co Inc
Inspection date
June 14, 2013
Product type
Biologics
Office
Center for Drug Evaluation and Research
People
  • Michael F. Skelly (issuing_officer)
  • Krystal Ogunremi (investigator)
  • Donald Arthur (company_representative)
  • Donald Dunham (company_representative)
  • Jackie Elboqin (company_representative)
View Company Profile

ID · ccb33ac0-ea38-43a2-95d1-abd75756e958

Violation Codes1
21 CFR 320.1(f)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Merck & Co Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.